Dupilumab for the Treatment of Atopic Dermatitis in an Austrian Cohort-Real-Life Data Shows Rosacea-Like Folliculitis

Dupilumab is the first biological treatment approved for moderate-to-severe atopic dermatitis (AD). Efficacy and safety have been demonstrated in clinical trials, but real-life data is still limited. The objective of this study was to retrospectively evaluate Dupilumab treatment in AD patients in a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Med
Main Authors: Quint, Tamara, Brunner, Patrick M., Sinz, Christoph, Steiner, Irene, Ristl, Robin, Vigl, Kornelia, Kimeswenger, Susanne, Neubauer, Katharina, Pirkhammer, Detlev, Zikeli, Martin, Hoetzenecker, Wolfram, Reider, Norbert, Bangert, Christine
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7230957/
https://ncbi.nlm.nih.gov/pubmed/32344789
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9041241
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados